The new LAMA/LABA inhalers could potentially reduce the use of ICS as part and parcel of maintenance therapy in COPD. Recent studies compared these LAMA/LABA inhalers with ICS/LABA combination inhalers in moderate-to-severe COPD. The results are promising and favor the LAMA...
Therefore, there is a concern about a possible increase in adverse events with LAMA/LABA combination therapy. LAMA/LABA FDC therapy is characterized by an excellent cardiovascular safety profile, at least in the patients with COPD who were enrolled in pivotal trials and who were devoid of major ...
Twelve studies’ data were derived from the individual components of subgroup analysis in the comparison of the LAMA/LABA combination therapy. Participants were at least 40 years of age, current or ex-smokers with a smoking history of 10 pack-years or more, and the severity of the disease ...
LABA (salmeterol) significantly improved asthma control when added to ICS compared with placebo (measured by Asthma Control Questionnaire [ACQ])21. The LTRA (montelukast) did not have an effect on asthma control when compared with placebo (measured by ACQ) (Table2)32. Data for LAMA (tiotropium...
GFF MDI (Bevespi Aerosphere®) is a fixed-dose combination (FDC) of GP (14.4 μg) and the LABA formoterol fumarate dihydrate (FF; 10 μg), delivered by a metered dose inhaler (MDI) using innovative co-suspension delivery technology [[17], [18], [19]]. GFF MDI is the first...
Combination bronchodilator agentsInhalersLABALAMAPharmacotherapyInhaled fixed-dose combinations (FDCs) of a long-acting 尾-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients. In this regard, global COPD ...
The current clinical use of LABA/LAMA combinations in COPD will continue to evolve as new trials with and without inhaled corticosteroids are completed. Expert opinion: Combining different classes of bronchodilators in a single inhaler is an attractive concept that can potentially improve patient ...
2 Olodaterol (Striverdi®; Boehringer Ingelheim Pharma GmbH & Co K.G., Ingelheim, Germany) is a LABA that provides 24-hr bronchodilation, and has been shown to improve lung function and reduce symptoms in patients with COPD. 3 When given in a fixed-dose combination with tiotropium via ...
Rationale: Current GOLD strategy document positions both combination regimens of inhaled corticosteroid plus a long-acting 尾2-agonist [i.e. ICS/LABA] and long-acting muscarinic antagonist plus LABA [i.e. LAMA/LABA] for symptomatic patients with recurrent exacerbations.Methods: The InforMing the ...
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) All-Cause Mortality Versus LAMA/LABA in COPD: Sensitivity Analysis of All-Cause Mortality (Secondary Endpoint) in the ETHOS Trial with Final Retrieved Vital Status Data